Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium breve B-3
- Development stage
- Unknown
- Lead developer
- Morinaga Milk Industry
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve B-3 is a proprietary human-residential probiotic strain of the species *Bifidobacterium breve*, developed by Morinaga Milk Industry. It is a non-motile, non-spore forming, rod-shaped anaerobic Gram-positive bacterium originally isolated from infant feces in 2009. This strain has been clinically studied for its effects on metabolic health and body composition. Clinical trials have shown that oral supplementation with *B. breve* B-3 can reduce body fat mass and percentage in pre-obese individuals without significant adverse effects[4][5][7]. Mechanistically, it supports healthy metabolism by modulating gut microbiota composition and function; it produces lactic and acetic acid in the gut to help break down food and absorb nutrients[1]. Additional studies suggest benefits for maintaining blood glucose, insulin sensitivity, cholesterol levels within normal ranges[3], enhancing intestinal barrier function[4], immune modulation (including upregulation of C3/CXCL6), and possibly increasing muscle mass when heat-killed preparations are used[7]. The safety of this strain has been confirmed through toxicity tests and genomic analysis.
- Brand names
- Morinaga B-3B-3-EXB3-EXB 3-EX
- Other names
- Bifidobacterium breve MCC1274Morinaga probiotic strain B-3
Beyond the preview
Go deeper on Bifidobacterium breve B-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium breve B-3.